Integrated safety across six clinical trials of alpha-1 augmentation therapy | European Respiratory SocietyR. SandhausK. R. ChapmanJ. BurdonE. PiitulainenN. SeersholmJ. StocksJ. EdelmanM. BexonL. HuangN. G. McElvaney (Denver
The available product, alpha 1-proteinase inhibitor, is derived from fractionated plasma and has similar biological activity to native serum AAT. Clinical trials have demonstrated a positive effect on serum and lung concentrations of AAT with few adverse events. Two recombinant forms of AAT have ...
Alvelestat (MPH966) for the treatment of ALpha-1 ANTitrypsin Deficiency (ATALANTa) 2018. https://clinicaltrials.gov/ct2/show/NCT03679598. Accessed 10 Mar 2021. Janus ED. Alpha 1-antitrypsin Pi types in COPD patients. Chest. 1988;94(2):446–7. Article CAS PubMed Google Scholar ...
Targeted beta therapyClinical trialsThis paper sets out to review all experimental and theoretical comparisons of efficacy and therapeutic gain for alpha and ... L Marcu,E Bezak,BJ Allen - 《Critical Reviews in Oncology/hematology》 被引量: 1发表: 2018年 Manual on the proper use of sodium ast...
retroviral, lentiviral, adenoviral, and adeno-associated viral (AAV) vectors has resulted in enhanced AAT serum levels and a promising safety profile. Human clinical trials using intramuscular viral transfer with AAV1 and AAV2 vectors of the AAT gene demonstrated its safety, but did not achieve ...
clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates may experience manufacturing or supply interruptions...
Background: The assessment of asthma control is pivotal to the evaluation of treatment response in individuals and in clinical trials. Previously, asthma control, severity, and exacerbations were de- fined and assessed in many different ... ABO Directors,EE Committie 被引量: 148发表: 2000年 Err...
1. Cheng, Y., He, C., Wang, M. et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Sig Transduct Target Ther 4, 62 (2019). 2. Chan-Penebre, E., Kuplast, K., Majer, C. et al. A selective inhibitor of PRMT5 with in vivo and...
FAO inhibitors, such as etomoxir, perhexiline, and ranolazine, have been approved by FDA and/or EMA for heart diseases and are currently being evaluated in various stages of clinical trials as anticancer agents54,55,56,57. Therefore, targeting FAO using these drugs might be a promising ...
关于临床试验ClinicalTrials.gov ID NCT05318092 临床试验联络人及地点 进行本研究的人员的联系方式,以及本研究正在何处进行的信息。 米国 亚利桑那州的位置 斯科茨代尔,亚利桑那州,米国,85258 HonorHealth 加州的位置 米国加利福尼亚州洛杉矶,邮编90404 加州大学...